May 19, 2011 - LifeVest Showcased at ESC 2011

MEDIA CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com

ZOLL LIFEVEST TO BE SHOWCASED AT EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE CONGRESS 2011

Wearable Defibrillator to be Discussed in Two Posters at Scientific Sessions

May 19, 2011CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, today announced that it will display the LifeVest® Wearable Defibrillator in Booth C03:11 at the European Society of Cardiology Heart Failure Congress 2011, being held from 21-24 May in Gothenburg, Sweden. The LifeVest will be discussed during two scientific/educational poster presentations.

These LifeVest presentations include:

  • Mitchell Saltzberg, M.D., Christina Care Health System, will present “Use of   a wearable defibrillator among pre-partum pregnant women: An analysis of safety, characteristics and outcomes,” Sunday, 22 May, 8:30 a.m., Poster Area – Poster Session 1: Left Ventricular Function.
  • Nicole Bianco, Ph.D, ZOLL Medical Corporation, will present “Rate of LV (left ventricular) systolic function recovery in cardiomyopathy patients prescribed wearable cardiac defibrillator,” Sunday, 22 May, 8:30 a.m., Poster Area – Poster Session 1: Left Ventricular Function.

“Heart failure affects approximately 30 million people in Europe and is the single biggest reason for acute hospital admission,” said Richard A. Packer, Chief Executive Officer of ZOLL. “The LifeVest is an important therapy in the continuum of care for patients with heart failure, providing their physician time to optimize their medical therapy while protecting them from sudden cardiac arrest.”

The LifeVest is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA.  The LifeVest continuously monitors the patient’s heart. If a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is used for a wide range of patient conditions, including following a heart attack, before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure that places patients at particular risk.

To date, the LifeVest has been prescribed for over 40,000 patients. 

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and related software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies.  With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Copyright © 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105.  LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.